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This report was compiled by Pavee Point Drugs Programme in consultation 
with local Traveller organisations.  Special thanks to Lisa Deegan, NUI 
Maynooth, for her assistance with analysing the data. 
 
 
Pavee Point Drugs Programme was established in 2000 and seeks to strengthen Travellers’ 
participation in responding to substance mis-use issues.  The central focus of the programme is the 
promotion of Traveller inclusion in national, regional and local responses being developed to 
address substance misuse and to support Traveller organisations in tackling this issue within their 
own community.   
Pavee Point Travellers Centre, 46 North Great Charles Street, Dublin 1 
Tel: 01 878 0255     Email: siobhan.cafferty@pavee.ie, johnpaul.collins@pavee.ie  
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Introduction 
The widespread use of benzodiazepines has been a cause for concern for many years by 
organisations within the drugs sector culminating in the establishment of the Benzodiazepine 
Committee and subsequent publication of the Good Practice Guidelines for Clinicians in 20021.  
Benzodiazepine refers to a wide range of drugs used as hypnotics, anxiolytics, tranquillisers, 
anticonvulsants and sedation.   Synonyms include sleeping tablets and tranquillizers while they are 
also known by their street names such as nerve tablets, benzos, valies, sleepers and downers2.  
It is nearly a decade since these good practice guidelines were published with no visible impact on 
prescribing practices or usage.  The lack of regulation has many adverse effects on the community – 
dependency, drug driving, workplace accidents and the creation of a black market to name a few.  
This report came about following numerous accounts of socio-economic problems stemming from 
benzodiazepine dependency amongst the Traveller community.  It examines the use of this 
particular group of drugs by the Traveller community based on anecdotal evidence collected by 
local Traveller organisations around Ireland.  It also sets out some recommended actions that could 
be implemented to effectively tackle the problem.   
Method 
 A questionnaire was disseminated to Traveller organisations working with their local community in 
order to assess their knowledge of the prevalence of benzodiazepine use and prescribing practices 
of clinicians in their area.  A total of 12 questionnaires were returned upon which this report is 
based.  These responses cover various regions of Ireland showing that this is not just an urban issue. 
A list of contributors is provided in appendix 2. 
It is important to bear in mind that the findings contained herein are based on local, anecdotal 
evidence and may not be representative of the entire Traveller population.  However, they do 
provide an indication of the extent of the problem, highlight the need for further research and the 
need to revisit the original guidelines with a view to develop tighter prescribing protocols. 
Following the collection of the initial findings, a national consultation process3 was held with 
Traveller organisations and service providers in order to develop recommended actions to alleviate 
the problem.   
Context 
Previous reports4 examining the use of benzodiazepines have tended to focus on a particular sub-
group of the general population i.e. those with an existing addiction and/or those engaging in drug 
and alcohol support services.  This report highlights the fact that the problem of benzodiazepine 
use and over prescribing practices are not exclusive to Travellers with a pre-existing alcohol or drug 
addiction.  Therefore, the NDTRS stats on the prevalence of benzodiazepine use only reflect the 
issue amongst the drug/alcohol addicted Traveller population.  While it is essential to continue to 
                                                          
1
 ‘Benzodiazepines: Good Practice Guidelines for Clinicians’, Dept of Health & Children, 2002. 
2 A reference list of pharmacological names for this group of drugs is included in the appendices. 
3
 Consultation process took place on July 26
th
 2011 as part of the Traveller Drug Network 
4
 National Drug Treatment Recording Statistics, HRB 
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gather these figures, they do not highlight the real extent of the problem within the entire 
community i.e. Travellers who are most likely to fall between the gaps of support services and who 
may not consider their benzodiazepine use a problem. 
The Report of the Benzodiazepine Committee acknowledges that the prescribing of these drugs is 
highly effective in the treatment of certain conditions and is necessary in some cases but also adds 
that, ‘nearly all the disadvantages of benzodiazepines have resulted from inappropriate long term 
use’.5  
 The good practice guidelines developed, as part of this committee’s remit, point out a number of 
recommendations that clinicians should refer to when prescribing benzodiazepines to patients and 
how to review usage.  These recommendations provide advice for clinicians but do not constitute a 
clear directive, therefore prescribing of benzodiazepines is still very much led by individual clinicians 
and can be influenced by patient demands.  It should be noted that many clinicians adhere to these 
recommendations and only prescribe these drugs when all other alternative forms of treatment 
have been explored.   
The Benzodiazepine Committee decided to produce practice guidelines rather than implement 
regulatory protocols as it was felt that, ‘this would be impractical because of the high level of 
legitimate medical usage of these drugs.’  Pavee Point Drugs Programme believe that this rationale 
for developing guidelines over protocols needs to be re-examined in light of these findings. 
Findings 
This report outlines numerous issues resulting from the mis-use of and/or over prescribing of 
benzodiazepines as experienced by the Traveller community.  Traveller organisations stated that 
these issues are experienced at every level from the individual, the immediate family and to the 
wider community.   
 There was unanimous agreement that the use of benzodiazepines was a problem for the Traveller 
community in each of the regions covered by the responding organisations.  Half of all 
respondents(n=6) also felt that the level of usage has increased over the past two years while the 
remainder were unsure.   
Prescribing practices 
Organisations reported many concerns regarding the prescribing practices of benzodiazepines 
leading to increased dependency on this group of drugs.  The top three most commonly reported 
problems with prescribing practices include: 
1) Treatment not regularly reviewed(n=9) 
2) Treatment prescribed for longer than 4 weeks(n=9) 
3) Referrals to support services not made(n=9) 
The occurrence of each of these issues contravenes the recommendations made in the good 
practice guidelines of 2002 and highlights the need for new regulations to be implemented if the 
                                                          
5
 The Report of the Benzodiazepine Committee, Dept of Health & Children, 2002, Pg 5 
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issue is to be tackled effectively.  National and international good practice indicates that 
benzodiazepines should not be prescribed for more than 2 to 4 weeks.  Organisations reported that 
prescriptions for up to two months were being given to some clients.  Resolution 44/13 of the 
Commission on Narcotic Drugs, which informed the Benzodiazepine Report, states health care 
professionals need to consider, ‘the setting of precise indications and prescriptions for the shortest 
possible period of time.’6  These findings show that this is clearly not being adhered to.  Table 1 
below highlights the remainder of the responses. 
Knowledge of general practitioners who prescribe large quantities of benzodiazepines, without 
asking too many questions, spreads fast.  Organisations are finding that people will travel long 
distances in order to obtain prescriptions from these particular GPs. 
Another identified issue is the obtaining of benzodiazepine prescriptions from more than one GP. 
Individuals then have access to huge quantities of legally prescribed medication that they then take 
themselves, give to others or sell on the black market.   
There are also reports that some Traveller women are obtaining prescriptions for their husbands 
without them receiving a full medical consultation.  In some cases, once a prescription has been 
previously written. Travellers only have to phone up their GP in order to get a repeat prescription 
filled.  This practice, again, contravenes the practice guidelines.  
Table 1: Most commonly reported problems with benzodiazepines by Traveller organisations 
 
 
 
                                                          
6
 Resolution 44/13. Contribution to the appropriate use of benzodiazepines, The commission on Narcotic 
Drugs. 
0 1 2 3 4 5 6 7 8
Full medical history not taken prior to prescribing
Presenting problem not fully explored
Alternative therapies not discussed/offered
Large quantities dispensed at one time
Patient not informed of side effects
Patient not informed of proper use of meds
Commonly reported problems
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Prevalence of use 
The overuse of benzodiazepines was reported to be more prevalent amongst adult Travellers with 
Traveller women identified as being most at risk of forming a dependency. This gender difference 
mirrors that of the majority population7.   
Traveller organisations reported that there appears to be a misconception that benzodiazepines are 
not harmful as they are prescribed by a medical professional.  This leads to increased use and a 
reluctance to accept that there is a problem on an individual and community basis. 
It was also noted that the overuse of medication is causing safety issues in homes and on the roads.  
Cookers, heating appliances and stoves are left unattended for long periods of time while someone 
is under the influence of these medications leaving their home and family members at risk.  Drug 
driving is also another potential hazard as improper use impairs a person’s ability to drive safely.  
Again, this is cited in Resolution 44/13 on the contribution to the appropriate use of 
benzodiazepines. 
Improper use of medication 
Organisations reported that the majority of Travellers that they were engaging with were not 
taking their medication as prescribed as they were not aware of how to do so.  In most cases, people 
were taking larger doses than prescribed by their clinician.   
Traveller organisations found that people tended to mis-use their medication in one of the 
following ways: 
1) Take all their medication over a shorter period in an attempt to feel better quicker e.g. 
taking a week’s supply in two days  
2) Self-medicate regularly i.e. increased their daily dose depending on how they were 
feeling or what was going on for them that day without being reviewed by a medical 
practitioner 
3) Shared their medication with other Travellers who seemed to have the same problem as 
them e.g. sleeping tablets or anti-depressants being given to others 
Impact of mis-use/over prescribing 
The overuse of benzodiazepines can impact on a person’s behaviour making them unpredictable 
while also impairing their ability to remember what they have done.  This problem can be 
exacerbated when a number of substances are ingested.   
The improper use of benzodiazepines, or combining their use with other substances, can also cause 
death by poisoning.  The National Drug Related Death Index has seen an increase in the number of 
deaths recorded where benzodiazepines were a factor8.   
                                                          
7
 ‘Problem benzodiazepine use in Ireland: treatment (2003 to 2008) and deaths(1998 to 2007)’, HRB, 2010 
8
 ibid 
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Traveller organisations also reported concerns that the use of benzodiazepines is seen as a way of 
coping with life circumstances leading to increased normalisation of their use which will impact on 
future generations of Travellers. 
Responses to the issue 
Half of all organisations(n=6) reported no local responses to the over prescribing and usage of 
benzodiazepines.  Two organisations stated that the local response involved education and 
awareness raising initiatives with Traveller Primary Health Care programmes where the information 
is then disseminated to the Traveller community. 
In all cases, respondents stated that a major awareness/education campaign needed to be devised 
in order to inform the Traveller community on the purpose and correct use of benzodiazepines.  The 
health implications of prolonged use and potentially fatal impact of poly-substance use also needs 
to be highlighted.  
An appropriate response to address the issue should involve tackling two key areas: 
 1) Regulation of prescribing practices by clinicians 
2) Awareness raising of the appropriate use of benzodiazepines within the Traveller 
community in order to change attitudes towards their usage 
Recommended Actions 
Pavee Point Drugs Programme, as part of their quarterly Traveller Drug Network, organised a 
consultation process with service providers and Traveller organisations from across Ireland in order 
to develop recommended actions to address the issues highlighted in this report. It was agreed that 
a collaborative approach needed to be undertaken combining the efforts of the Traveller 
community, organisations and the Government if benzodiazepine use is to be tackled effectively.   
Actions are required at three levels: 
1. Local Traveller communities 
2. Local & National Traveller organisations 
3. Government  
Action 1: Travellers’ need support to ensure they can take ownership over their own health and 
the general well-being of their community 
Suggested lead agencies: Members of the Traveller community in conjunction with local Traveller 
organisations 
Members of the Traveller community play a vital role in ensuring they receive the appropriate care 
from their clinician.  This can be achieved by developing the community’s capacity to ask questions 
during consultations, ensuring they are receiving the best care and re-balancing the doctor/patient 
relationship. 
 
If a member of the Traveller community feels they have received poor care from a medical 
professional, they should be assisted by their local Traveller organisation to make a complaint 
through the existing Health Service Executive initiative, ‘Have your say’. 
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Action 2: Pro-active measures need to be taken by Travellers if attitudes towards the sharing of 
prescribed medication are to change 
Suggested lead agencies: Local and National Traveller organisations 
Attitudes regarding the commonly accepted practice of sharing prescribed medications need to be 
challenged and actively discouraged.  Local and National Traveller organisations play a key role in 
educating members of the Traveller community and challenging this practice in order to break it.   
 
Action 3: Raise awareness of alternative options other than prescribed medication 
Suggested lead agencies:  Irish medical council, Traveller counselling service & Pavee Point Drugs 
Programme 
All other options should be exhausted prior to the prescribing of benzodiazepines.  GPs should refer 
patients to counseling if this is at all appropriate to treat their patient’s condition.  GPs should be 
made aware of the Traveller specific counselling services available to their patients as an option for 
alternative treatment.   
 
The expectation of some Travellers that they will only be effectively treated when they receive a 
prescription for medication needs to be challenged at local and national level. 
 
Action 4: A public awareness campaign needs to be developed and supported by the Drugs 
Advisory Group 
Suggested lead agencies: Health Service Executive & the Drugs Advisory Group in consultation with 
local groups 
As this report highlights the level of benzodiazepine use amongst a cohort of a community not 
engaging with support services, the most effective way to spread the message would be through a 
national public awareness campaign.  To overcome the literacy issue, a visual format such as a DVD 
was felt to be the most appropriate mechanism for disseminating the message.  Alternatively, a 
national radio advert would have the same effect. 
 
Local awareness raising initiatives examining the correct use of benzodiazepines should be 
undertaken by local and national Traveller organisations while the public awareness campaign is 
being developed. 
 
Action 5: Classification of benzodiazepines needs to be re-examined 
Suggested lead agency: Drug Advisory Group 
The most commonly abused benzodiazepines should have their classification re-examined from 
Schedule 4 to Schedule 3 to ensure tighter controls regarding their prescribing and storage.  A 
phased in approach should be taken for individuals who have an existing dependency on 
benzodiazepines to avoid any potential negative side effects. 
 
Action 6: A national monitoring system needs to be developed to record the number of 
benzodiazepine prescriptions per GP and individual 
Suggested lead agencies: Health Service Executive, Irish Medical Council & the Irish Pharmacy Union 
A universal networked monitoring system needs to be developed across all dispensing pharmacies 
to capture the number of benzodiazepines prescribed per GP and to each individual.  This system 
should alert dispensing pharmacists if the number of benzodiazepine prescriptions are above a 
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national average for a GP or if an individual has been prescribed too many within a particular period 
of time. 
 
For this system to work effectively and to counteract the number of individuals using someone 
else’s medical card, it should be based on PPS numbers and photographic identification.  If an 
individual presents to a number of pharmacies seeking benzodiazepines to be dispensed this 
networked system will alert the pharmacist. 
 
Action 7: Current prescribing guidelines to be upgraded to protocols 
Suggested lead agency: Drugs Advisory Group 
The current benzodiazepine prescribing guidelines, of 2002, need to be upgraded to clear protocols 
ensuring greater accountability and consistency amongst clinicians.  Any clinician found to be in 
breach of these protocols should be answerable to the relevant authorities with repeat offences 
leaving them liable to be struck off the register.   
 
The existing level of dependency for individuals needs to be taken into consideration should 
protocols be introduced. A suggested ‘phase in’ initiative providing support to such individuals 
would assist with the transition from guidelines to protocols. 
 
Action 8: National benzodiazepine helpline to be established 
Suggested lead agency: Health Service Executive 
A national helpline, similar to the Quit Smoking helpline, should be developed to coincide with the 
launch of prescribing protocols.  Any individual who is concerned about their level of 
benzodiazepine use can have access to immediate support while also maintaining their anonymity. 
 
Action 9: Measures need to be put in place to reduce the level of benzodiazepines available on 
the black market 
Suggested lead agency: An Garda Síochana 
A Garda operation specifically targeting the number of illicit benzodiazepines making it into Ireland 
via the internet or smuggling through airports needs to be established.  Close monitoring of inward 
deliveries from websites that sell such medication needs to be developed to reduce the number of 
illegal benzodiazepines making it to the streets.  
 
Conclusion 
The use of benzodiazepines, within an Irish context, has consistently been raised as a cause for 
concern by addiction support groups and communities for over a decade now.  During this time, 
many reports have been published highlighting the fact that there are large cohorts of the 
population that are dependent on this class of drugs.  This report has set out nine suggested 
recommendations for action that, if implemented, would make an impact on the level of 
benzodiazepine use within Ireland in general.  
Using current usage trends as an indicator, we can assume that the rates of dependency will 
continue to increase over the next ten years, unless direct action is taken.   
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Appendix 1: Benzodiazepine table 
Category of drug Name Producer Street name 
Anxiolytics: 
Anti-anxiety drugs 
Diazepam Valium Vallies 
Alprazolam Alprox 
Calmax 
Gerax 
Xanax 
Xanies 
Bromazepam Lexotan  
Chlordiazepoxide Librium  
Clobazam Frisium  
Chlorazepate Tranxene  
Hypnotics: 
Sleep inducing drugs 
Flunitrazepam Rohypnol Date rape drug 
Roofies 
Flurazepam Dalmane  
Loprazolam Dormonoct  
Lormetazepam Noctamid  
Nitrazepam Mogadon 
Somnite 
Moggies 
Temazepam Normison 
Nortem 
Tenox 
Temazzies  
Normies 
 
Appendix two: Report contributors 
Organisation Area covered 
Clondalkin Travellers Development Group Clondalkin 
Lucan 
Newcastle 
Palmerstown 
Kerry Travellers Development Project County Kerry 
Galway Traveller Movement South East Galway 
Galway Traveller Movement – Youth Programme Galway City 
Longford Primary Health Care Programme for 
Travellers 
County Longford 
Tullamore Primary Health Care Programme County Offaly 
CDA Trust Ltd Cavan 
Monaghan 
Cork Traveller Visibility Group Cork City 
Wicklow Travellers Group County Wicklow 
DAISH  Bray 
North Wicklow 
South Dublin 
Traveller Health HSE & Mayo Travellers Support County Mayo 
Western Traveller Intercultural & Development Tuam, Co. Galway 
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